Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer
- 17 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Prostate Cancer and Prostatic Diseases
- Vol. 23 (4), 705-713
- https://doi.org/10.1038/s41391-020-0224-4
Abstract
Background The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive and prognostic biomarkers for metastatic castration-resistant prostate cancer (mCRPC). Methods Serial plasma specimens were prospectively collected from 88 chemotherapy-naive mCRPC patients before and after 12 weeks of AA/P treatment. Sequencing-based CNA analyses were performed on 174 specimens. We evaluated CNA-associated 12-week responses for primary resistance, time to treatment change (TTTC) for secondary resistance, and overall survival for prognosis (P < 0.05). Associations with primary resistance were analyzed using the Fisher exact test. Kaplan-Meier survival curves and Cox regression analyses were used to determine the associations of CNAs with acquired resistance and overall survival. Results ctDNA reduced by 3.89% in responders and increased by 0.94% in nonresponders (P = 0.0043). Thirty-one prostate cancer-related genes from whole genome CNAs were tested. AR and AR enhancer amplification were associated with primary resistance (P = 0.0039) and shorter TTTC (P = 0.0003). ZFHX3 deletion and PIK3CA amplification were associated with primary resistance (P = 0.026 and P = 0.017, respectively), shorter TTTC (P = 0.0008 and P = 0.0016, respectively), and poor survival (P = 0.0025 and P = 0.0022, respectively). CNA-based risk scores combining selected significant associations (AR, NKX3.1, and PIK3CA) at the univariate level with TTTC were predictive of secondary resistance (P = 0.0002). and established prognoses for survival based on CNAs in ZFHX3, RB1, PIK3CA, and OPHN1 (P = 0.002). Multigene risk scores were more predictive than individual genes or clinical risk factors (P < 0.05). Conclusion Plasma ctDNA CNAs and risk scores can predict mCRPC-state treatment and survival outcomes.Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (CA212097, CA212097)
- U.S. Department of Health & Human Services | National Institutes of Health
This publication has 45 references indexed in Scilit:
- Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapyTherapeutic Advances in Urology, 2015
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerClinical Cancer Research, 2015
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- Oligophrenin-1 Is Associated with Cell Adhesion and Migration in Prostate CancerPathobiology, 2014
- Castration-Resistant Prostate Cancer: From New Pathophysiology to New TreatmentEuropean Urology, 2013
- Punctuated Evolution of Prostate Cancer GenomesCell, 2013
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyThe New England Journal of Medicine, 2013
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate CancerClinical Cancer Research, 2007